Harmony Biosciences Holdings, Inc.

NasdaqGM HRMY

Harmony Biosciences Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD 220.18 M

Harmony Biosciences Holdings, Inc. Free Cash Flow is USD 220.18 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 5.16% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Harmony Biosciences Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 209.37 M, a -2.82% change year over year.
  • Harmony Biosciences Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 215.45 M, a 789.94% change year over year.
  • Harmony Biosciences Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -31.23 M, a 72.62% change year over year.
  • Harmony Biosciences Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -114.06 M.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
NasdaqGM: HRMY

Harmony Biosciences Holdings, Inc.

CEO Dr. Jeffrey M. Dayno M.D.
IPO Date Aug. 19, 2020
Location United States
Headquarters 630 West Germantown Pike
Employees 246
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Similar companies

VRNA

Verona Pharma plc

USD 48.44

3.75%

JANX

Janux Therapeutics, Inc.

USD 45.35

0.64%

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

VTYX

Ventyx Biosciences, Inc.

USD 1.94

-0.51%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

PTGX

Protagonist Therapeutics, Inc.

USD 36.67

-1.26%

NVCT

Nuvectis Pharma, Inc.

USD 5.64

-2.93%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

PLRX

Pliant Therapeutics, Inc.

USD 11.24

-4.50%

VRDN

Viridian Therapeutics, Inc.

USD 16.86

-5.12%

FENC

Fennec Pharmaceuticals Inc.

USD 5.64

-3.09%

GPCR

Structure Therapeutics Inc.

USD 25.38

0.87%

TVTX

Travere Therapeutics, Inc.

USD 17.07

-8.18%

REPL

Replimune Group, Inc.

USD 10.49

-3.67%

IDYA

IDEAYA Biosciences, Inc.

USD 22.74

-1.00%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

KROS

Keros Therapeutics, Inc.

USD 12.48

-2.65%

StockViz Staff

January 15, 2025

Any question? Send us an email